2Ouzan J,Perault C,Lineoff AM,et al. The role of spironolactone in the treatment of patients with refractory hypertension [J]. Am J Hypertens,2002,15(4 Pt 1) :333-339.
3Chapman N,Dobson J,Wilson S, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension [J]. Hypertension,2007,49(4):839-845.
4Dietz JD, Du S, Bolten CW, et al. A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity [ J ]. Hypertension, 2008, 51 ( 3 ) : 742-748.
5Ljung B. Vascular selectivity of felodipine[J]. Drugs, 1985,29 (Suppl 2) :46-58.
4Steiner S, Helis E, Chen L, et al. A cross-national comparative study of blood pressure levels and hypertension prevalence in Canada and Hungary [J]. J Hypertens, 2012,30(11):2105- 2111.
5Butler J,Rodondi N,Zhu Y,et al. Metabolic syndrome and the risk of cardiovascular disease in older adults [J]. J Am Coil Cardiol, 2006,47 (8) :1595-602.
6Ko GT, So WY, Chan NN, et and total mortality in Chinese al. Prediction of cardiovascular type 2 diabetic patients by the WHO definition for the metabolic syndrome[J]. Diabetes Obes Metab,2006,8(1) :94-104.
7Singh IM,Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target : a systematic review [J]. JAMA, 2007, 298(7) : 786-798.
8Kim KI, Oh SW, Ahn S, et al. CRP level and HDI. cholesterol concentration jointly predict mortality in a Korean population [J]. Am J Med,2012,125(8),787-795.
9Huxley RR, Barzi F, Lam T H, et al. Isolated low levels of highdensity lipoprotein cholesterol are associated with an increased risk of coronary heart disease: an individual participant data meta-analysis of 2a studies in the Asia-Pacific region[J]. Circulation, 2011,124(19) : 2056-2064.
